Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, First in Human, Dose Escalation Trial of TL 895 Monotherapy in Subjects With Relapsed/Refractory B Cell Malignancies and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Subjects and Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma

NCT02825836 is registered in ClinicalTrials.gov with Telios Pharma, Inc. as lead sponsor.

NCT NCT02825836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02825836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, First in Human, Dose Escalation Trial of TL 895 Monotherapy in Subjects With Relapsed/Refractory B Cell Malignancies and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Subjects and Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma
Lead sponsor
Telios Pharma, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 26, 2016
Completion date
December 1, 2025
Enrollment
130 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, mantle cell lymphoma and diffuse large b cell lymphoma, relapsed/refractory b cell malignancies, small lymphocytic lymphoma, treatment-naive b cell malignancies